Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial

Chronic hepatitis B (CHB) remains a major worldwide public health concern. Besifovir dipivoxil maleate (BSV) is a new promising treatment for CHB. However, long-term efficacy and safety have not yet been evaluated. Therefore, the goal of the study is to determine the antiviral efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yim, Hyung Joon, Kim, Won, Ahn, Sang Hoon, Yang, Jin Mo, Jang, Jae Young, Kweon, Yong Oh, Cho, Yong Kyun, Kim, Yoon Jun, Hong, Gun Young, Kim, Dong Joon, Jung, Young Kul, Um, Soon Ho, Sohn, Joo Hyun, Lee, Jin Woo, Park, Sung Jae, Lee, Byung Seok, Kim, Ju Hyun, Kim, Hong Soo, Yoon, Seung Kew, Kim, Moon Young, Lee, Kwan Sik, Lim, Young Suk, Lee, Wan Sik, Han, Kwang-Hyub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402376/
https://www.ncbi.nlm.nih.gov/pubmed/32355123
http://dx.doi.org/10.14309/ajg.0000000000000605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402376/
https://www.ncbi.nlm.nih.gov/pubmed/32355123
http://dx.doi.org/10.14309/ajg.0000000000000605

Ejemplares similares